Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(6):1052–1058. doi: 10.1038/sj.bjc.6690806

Predictive value of decreased p27Kip1 protein expression for the recurrence-free and long-term survival of prostate cancer patients

M Kuczyk 1, S Machtens 1, K Hradil 1, J Schubach 1, W Christian 1, R Knüchel 3, J Hartmann 2, C Bokemeyer 2, U Jonas 1, J Serth 1
PMCID: PMC2362945  PMID: 10576664

Abstract

The p27Kip1 gene has been identified as inductor of cell cycle arrest at the G1 checkpoint to prevent entry of somatic cells into the S phase of the cell cycle when substantial DNA damage has occurred. It has been suggested that decreased expression of the p27Kip1 protein may contribute to the development of human malignancies due to loss of critical antiproliferative mechanisms. In the present study, 95 specimens (T1–T4) from 95 randomly selected patients undergoing radical prostatectomy at the Urological Department of Hannover University (82 patients) as well as in the Josef Hospital Regensburg (13 patients) between 1981 and 1992 for whom tissue blocks for immunohistochemical investigation were available, were investigated for different biological and clinical characteristics as possible predictors for recurrence-free and long-term survival: age, depth of tumour infiltration, histological grade, lymph node status, as well as decreased expression of the p27Kip1 protein. After a median follow-up up of 56 months (24–151 months), seven of 21 (33%) patients (Group 1) with loss of p27Kip1 protein expression or a relative amount of <10% of positively stained tumour cells developed recurrent disease in contrast to 17 of 74 (23%) patients (Group 2) with retained p27Kip1 protein expression (≥10% of positively stained tumour cells). The median recurrence-free survival was 14 months (5–40 months) for patients from Group 1 and 31 months (7–133 months) for Group 2 patients (P = 0.02). In multivariate analysis, loss of p27Kip1 protein expression was identified as the only independent prognostic parameter for recurrence-free survival. In contrast, neither the univariate nor the multivariate analysis showed a correlation between loss of p27Kip1 protein expression and the long-term survival of the patients. Prospective studies are urgently needed to confirm the independent prognostic value of decreased p27Kip1 protein expression together with overexpression of the p53 tumour suppressor protein in patients with localized prostate cancer. The availability of more refined prognostically important biological variables in addition to established prognostic factors like tumour stage or Gleason score might help decision making in patients at high risk for the development of local recurrence or systemic tumour progression. © 1999 Cancer Research Campaign

Keywords: prostate cancer, prognosis, p27Kip1 gene

Full Text

The Full Text of this article is available as a PDF (197.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman D. A., Barry J. M., Wicklund R. A., Olson N., Lowe B. A. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol. 1993 Dec;150(6):1845–1850. doi: 10.1016/s0022-5347(17)35912-8. [DOI] [PubMed] [Google Scholar]
  2. Adolfsson J., Carstensen J., Löwhagen T. Deferred treatment in clinically localised prostatic carcinoma. Br J Urol. 1992 Feb;69(2):183–187. doi: 10.1111/j.1464-410x.1992.tb15493.x. [DOI] [PubMed] [Google Scholar]
  3. Bullrich F., MacLachlan T. K., Sang N., Druck T., Veronese M. L., Allen S. L., Chiorazzi N., Koff A., Heubner K., Croce C. M. Chromosomal mapping of members of the cdc2 family of protein kinases, cdk3, cdk6, PISSLRE, and PITALRE, and a cdk inhibitor, p27Kip1, to regions involved in human cancer. Cancer Res. 1995 Mar 15;55(6):1199–1205. [PubMed] [Google Scholar]
  4. Cote R. J., Shi Y., Groshen S., Feng A. C., Cordon-Cardo C., Skinner D., Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998 Jun 17;90(12):916–920. doi: 10.1093/jnci/90.12.916. [DOI] [PubMed] [Google Scholar]
  5. Craig C., Wersto R., Kim M., Ohri E., Li Z., Katayose D., Lee S. J., Trepel J., Cowan K., Seth P. A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. Oncogene. 1997 May 15;14(19):2283–2289. doi: 10.1038/sj.onc.1201064. [DOI] [PubMed] [Google Scholar]
  6. Elledge S. J. Cell cycle checkpoints: preventing an identity crisis. Science. 1996 Dec 6;274(5293):1664–1672. doi: 10.1126/science.274.5293.1664. [DOI] [PubMed] [Google Scholar]
  7. Esposito V., Baldi A., De Luca A., Groger A. M., Loda M., Giordano G. G., Caputi M., Baldi F., Pagano M., Giordano A. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res. 1997 Aug 15;57(16):3381–3385. [PubMed] [Google Scholar]
  8. Ferrando A. A., Balbín M., Pendás A. M., Vizoso F., Velasco G., López-Otín C. Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. Hum Genet. 1996 Jan;97(1):91–94. doi: 10.1007/BF00218840. [DOI] [PubMed] [Google Scholar]
  9. Fredersdorf S., Burns J., Milne A. M., Packham G., Fallis L., Gillett C. E., Royds J. A., Peston D., Hall P. A., Hanby A. M. High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6380–6385. doi: 10.1073/pnas.94.12.6380. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. George N. J. Natural history of localised prostatic cancer managed by conservative therapy alone. Lancet. 1988 Mar 5;1(8584):494–497. doi: 10.1016/s0140-6736(88)91294-9. [DOI] [PubMed] [Google Scholar]
  11. Johansson J. E., Adami H. O., Andersson S. O., Bergström R., Holmberg L., Krusemo U. B. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992 Apr 22;267(16):2191–2196. [PubMed] [Google Scholar]
  12. Kato J. Y., Matsuoka M., Polyak K., Massagué J., Sherr C. J. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell. 1994 Nov 4;79(3):487–496. doi: 10.1016/0092-8674(94)90257-7. [DOI] [PubMed] [Google Scholar]
  13. Kawamata N., Seriu T., Koeffler H. P., Bartram C. R. Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer. 1996 Feb 1;77(3):570–575. doi: 10.1002/(SICI)1097-0142(19960201)77:3<570::AID-CNCR21>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  14. Kawasaki T., Tomita Y., Bilim V., Takeda M., Takahashi K., Kumanishi T. Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int J Cancer. 1996 Nov 15;68(4):501–505. doi: 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  15. Kuczyk M. A., Serth J., Bokemeyer C., Machtens S., Minssen A., Bathke W., Hartmann J., Jonas U. The prognostic value of p53 for long-term and recurrence-free survival following radical prostatectomy. Eur J Cancer. 1998 Apr;34(5):679–686. doi: 10.1016/s0959-8049(97)10112-5. [DOI] [PubMed] [Google Scholar]
  16. Lee C. C., Yamamoto S., Wanibuchi H., Wada S., Sugimura K., Kishimoto T., Fukushima S. Cyclin D1 overexpression in rat two-stage bladder carcinogenesis and its relationship with oncogenes, tumor suppressor genes, and cell proliferation. Cancer Res. 1997 Nov 1;57(21):4765–4776. [PubMed] [Google Scholar]
  17. Martin E., Cacheux V., Cavé H., Lapierre J. M., Le Paslier D., Grandchamp B. Localization of the CDKN4/p27Kip1 gene to human chromosome 12p12.3. Hum Genet. 1995 Dec;96(6):668–670. doi: 10.1007/BF00210296. [DOI] [PubMed] [Google Scholar]
  18. McGarvey T. W., Malkowicz S. B. The role of the cell cycle in genitourinary carcinoma. World J Urol. 1996;14(5):310–317. doi: 10.1007/BF00184603. [DOI] [PubMed] [Google Scholar]
  19. Nasmyth K. Viewpoint: putting the cell cycle in order. Science. 1996 Dec 6;274(5293):1643–1645. doi: 10.1126/science.274.5293.1643. [DOI] [PubMed] [Google Scholar]
  20. Parker S. L., Tong T., Bolden S., Wingo P. A. Cancer statistics, 1996. CA Cancer J Clin. 1996 Jan-Feb;46(1):5–27. doi: 10.3322/canjclin.46.1.5. [DOI] [PubMed] [Google Scholar]
  21. Polyak K., Kato J. Y., Solomon M. J., Sherr C. J., Massague J., Roberts J. M., Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev. 1994 Jan;8(1):9–22. doi: 10.1101/gad.8.1.9. [DOI] [PubMed] [Google Scholar]
  22. Polyak K., Lee M. H., Erdjument-Bromage H., Koff A., Roberts J. M., Tempst P., Massagué J. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994 Jul 15;78(1):59–66. doi: 10.1016/0092-8674(94)90572-x. [DOI] [PubMed] [Google Scholar]
  23. Ponce-Castañeda M. V., Lee M. H., Latres E., Polyak K., Lacombe L., Montgomery K., Mathew S., Krauter K., Sheinfeld J., Massague J. p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res. 1995 Mar 15;55(6):1211–1214. [PubMed] [Google Scholar]
  24. Porter P. L., Malone K. E., Heagerty P. J., Alexander G. M., Gatti L. A., Firpo E. J., Daling J. R., Roberts J. M. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med. 1997 Feb;3(2):222–225. doi: 10.1038/nm0297-222. [DOI] [PubMed] [Google Scholar]
  25. Spirin K. S., Simpson J. F., Takeuchi S., Kawamata N., Miller C. W., Koeffler H. P. p27/Kip1 mutation found in breast cancer. Cancer Res. 1996 May 15;56(10):2400–2404. [PubMed] [Google Scholar]
  26. Stamey T. A., Freiha F. S., McNeal J. E., Redwine E. A., Whittemore A. S., Schmid H. P. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer. 1993 Feb 1;71(3 Suppl):933–938. doi: 10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l. [DOI] [PubMed] [Google Scholar]
  27. Wu G., Fan R. S., Li W., Ko T. C., Brattain M. G. Modulation of cell cycle control by vitamin D3 and its analogue, EB1089, in human breast cancer cells. Oncogene. 1997 Sep 25;15(13):1555–1563. doi: 10.1038/sj.onc.1201329. [DOI] [PubMed] [Google Scholar]
  28. Yang R. M., Naitoh J., Murphy M., Wang H. J., Phillipson J., deKernion J. B., Loda M., Reiter R. E. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998 Mar;159(3):941–945. [PubMed] [Google Scholar]
  29. Yasui W., Kudo Y., Semba S., Yokozaki H., Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 1997 Jul;88(7):625–629. doi: 10.1111/j.1349-7006.1997.tb00428.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES